First Derivatives CEO diagnosed with cancer
THE CEO of Newry-based First Derivatives, Brian Conlon, has been diagnosed with cancer.
Mr Conlon (53) will remain in the CEO role during his ongoing treatment, which includes chemotherapy. This treatment is expected to last a number of months, the group, which is one of the biggest employers of graduates in Ireland, said.
Please log in or register with Independent.ie for free access to this article.
Seamus Keating, chairman of First Derivatives, will provide additional executive and governance support while Mr Conlon is receiving care.
"The board has set a clear strategy and the Executive Committee, led by Brian, has delivered strong execution of that strategy year-on-year," Mr Keating said. "During the period of his treatment I will provide additional executive and governance support and I am confident that Brian and his team will continue to execute the group's growth plans successfully."
Yesterday shares in the group were down 1.3pc in afternoon trading. The company, founded by Newry-born Mr Conlon (pictured) in 1996, provides software, consulting and data analytics products and services, initially to the investment banking sector but increasingly to non-financial sectors.
First Derivatives operates from 14 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,600 people worldwide.
In its most recent results covering the six months to August 31, 2018, the company reported adjusted profit after tax of £10.6m (€12.1m).